The Chinese Patent Office has issued a Notice of Allowance for a patent application related to ICOres®, which means that Iconovo will receive patent protection for the inhaler in China until 2040 after a series of administrative steps. ICOres® is already protected by patents in Europe (EPO), Sweden, India, Japan and the USA.

”The preliminary notification from the Chinese Patent Office strengthens our intellectual property rights in China and enhances the value of our product portfolio. China is a fast-growing market and already one of the largest pharmaceutical markets in the world. Reservoir inhalers are of particular interest in China where Turbuhaler® from AstraZeneca is successful and inhalers with many doses are popular, ” says Roger Lassing, Vice President of Business Development at Iconovo.

About ICOres

ICOres is a flexible multi-dose dry powder inhaler with feedback features developed by Iconovo. ICOres is a reservoir inhaler similar in handling to AstraZeneca’s best-selling Turbuhaler®. It features two separate reservoirs which allow for simultaneous inhalation of two different formulations that makes it suitable for combination products. Its intuitive handling, exact dose counting, and clear inhalation feedback helps the patient to stay compliant with the treatment. ICOres is ready for commercial manufacturing making it the best alternative for pharmaceutical companies seeking a reservoir inhaler.